All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
Treatment sequencing for anemic myelofibrosis
with Jean-Jacques Kiladjian & Angela Fleischman
Monday, February 26, 2024 | 16:30 CET
This independent educational activity is supported by Bristol Myers Squibb. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
One thousand patients with ET: Patient characteristics, management, and clinical outcomes
Here, we summarize the characteristics, management strategies and clinical outcomes in two cohorts of patients with essential thrombocythemia, from the United...
Primary myelofibrosis: Prognostic impact of non-driver mutations
Here, we summarize results from a multivariate analysis by Hernández-Sánchez et al. published in American Journal of Hematology investigating the impact of non-myeloproliferative...